TC
VERV

TwinBeech Capital’s Verve Therapeutics VERV Stock Holding History

TwinBeech Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-143,520
Closed -$2.07M – 877
2023
Q1 		$2.07M Buy
143,520
+80,177
+127% +$1.57M 0.04% 373
2022
Q4 		$1.23M Buy
+63,343
New +$1.68M 0.02% 499

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

TwinBeech Capital's VERV Position: Q2 2023 in Review

TwinBeech Capital sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 143,520 shares — an estimated $2.07M sold.

TwinBeech Capital first reported a position in VERV in Q4 2022 and held it in 2 quarters. The position peaked at $2.07M in Q1 2023. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • TwinBeech Capital reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TwinBeech Capital sold 143,520 Verve Therapeutics shares in Q2 2023, an estimated $2.07M.
  • TwinBeech Capital first reported a position in Verve Therapeutics in Q4 2022 and held it in 2 quarters.
  • TwinBeech Capital's Verve Therapeutics position peaked at $2.07M in Q1 2023.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on TwinBeech Capital's 13F filing for Q2 2023, filed 14 Aug 2023.